Summary
Assembles FDA IND filing precedents, module-level requirements, and common deficiency analysis to accelerate IND preparation and reduce clinical hold risk.
Detailed Description
The FDA IND Strategy Pack streamlines Investigational New Drug application preparation by compiling filing precedents, module-level content requirements, and historical clinical hold analysis. It draws on FDA guidance documents, published IND filing strategies, and CDER review standards to help sponsors prepare complete and defensible IND submissions.
The pack analyzes common clinical hold reasons by therapeutic area and development phase, identifies frequently cited deficiencies in FDA information requests, and maps the module-level content expectations for each IND section. It provides a structured gap analysis comparing your existing documentation against FDA requirements.
Deliverables include an IND readiness assessment, a module-by-module gap analysis with remediation priorities, and a clinical hold risk mitigation checklist derived from historical hold patterns in your therapeutic area.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA IND Guidance Library | REGULATORY | FDA guidance documents on IND content requirements, pre-IND meetings, and filing procedures | Monthly |
| Clinical Hold Database | REGULATORY | Historical analysis of FDA clinical holds by therapeutic area, phase, and deficiency type | Quarterly |
| IND Filing Precedents | CURATED | Curated database of IND filing strategies with outcomes and lessons learned | Monthly |
Regulatory Mapping
Investigational New Drug Application
Common Technical Document for the Registration of Pharmaceuticals for Human Use
IND Applications Prepared and Submitted by Sponsor-Investigators
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
IND Readiness Assessment
PDFComprehensive evaluation of IND readiness across all CTD modules with risk scoring
Module Gap Analysis
XLSXModule-by-module gap analysis with specific deficiency identification and remediation priorities
Clinical Hold Risk Checklist
PDFRisk mitigation checklist derived from historical clinical hold patterns
Deliverables included
- IND readiness assessment with risk scoring
- Module-by-module content gap analysis
- Clinical hold risk mitigation checklist
- Pre-IND meeting request strategy and briefing document outline
- IND filing timeline with critical path analysis
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Cross-Therapeutic | Regulatory Strategy | N/A — regulatory focus | Primary |
| Oncology | Accelerated Approval Programs | ORRDORctDNA response | Secondary |
Related Packs in Regulatory Strategy
FDA/EMA Alignment Pack
Harmonize your global regulatory strategy
Breakthrough/Fast Track Evidence Pack
Maximize your chances for expedited designation
Pre-Submission Meeting Prep Pack
Walk into every FDA meeting fully prepared
Global Regulatory Intelligence Pack
Track regulatory shifts across 40+ markets in real time
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.